Lunit vs Qure.ai vs Shukun 数坤科技 vs Viz.ai
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Lunit
KOSDAQ-listed Korean AI for breast and chest cancer screening
Visit
|
|
Shukun 数坤科技
Beijing imaging AI with China's most Class III approvals, by its own c...
Visit
|
Viz.ai
AI that flags suspected strokes on scans and pages the care team
Visit
|
|
|---|---|---|---|---|
| RECATOOLS Score | 6.7 / 10 | 8.2 / 10 | 6.8 / 10 | 8.2 / 10 |
| Capability | ||||
| Value for money | ||||
| Ease of use | ||||
| ASEAN readiness | ||||
| API quality | ||||
| Pricing | Enterprise | Enterprise | Enterprise | Enterprise |
| Free tier | — | No free tier; enterprise contracts only; trial demos available via sales | — | — |
| Paid from | No public $ price — quoted per institution via Lunit sales and imaging partners | Custom enterprise pricing; contact sales for per-scan or site-licence quotes | Quoted on request (hospital and distributor sales, trial by application) | Quoted on request (demo and sales contact only, no published price) |
| Has API | ✗ | ✓ | ✗ | ✓ |
| Open source | ✗ | ✗ | ✗ | ✗ |
| Free to use | ✗ | ✗ | ✗ | ✗ |
| Users | — | 34M+ lives impacted across 4,800+ clinical sites in 105+ countries (as of late 2025) | — | Nearly 2,000 U.S. hospitals; 60,000+ providers; 230M+ lives covered |
| Founded | 2015 | 2016 | 2017 | 2016 |
| Maker | — | Independent (Series D — Lightspeed, 360 ONE Asset, Merck GHI Fund) | — | Dr. Chris Mansi (CEO, neurosurgeon) and Dr. David Golan (CTO, machine learning researcher) |
| Verdict | Lunit is one of the few medical-AI vendors with substantial revenue behind it: KRW 45.8 billion in the first half of 2026, up 23%, almost all earned abroad, though it is still loss-making and completed a KRW 211.5 billio... |
Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations... |
Shukun's case rests on approvals and breadth: 18 Chinese Class III certificates by its count, MDR CE marks across cardiac, stroke and other tools, PMDA approvals in Japan and three FDA 510(k) clearances, including Corona... |
Viz.ai pioneered AI stroke triage, and its 2018 De Novo authorisation is still the reference point for the category. Today it is a broad care-coordination platform in about 2,000 US hospitals, with 13 FDA clearances behi... |
| Full review → | Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.